
|Articles|July 1, 2001
Pimecrolimus impresses: ASM 981 cream reduces flares of pediatric
Portland, Ore. - The topical immunomodulator pimecrolimus cream 1 percent (ASM 981, Elidel) significantly reduces flares without systemic adverse events in children with atopic dermatitis, according to researchers.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 2
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















